Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Commercial Standouts Lacking Among 2016 US Launches

Executive Summary

The number of novel drugs approved by FDA in 2016 was down versus prior years, and many of the drugs that did launch are off to a slow start. The expectation is increasingly for drugs to build sales over time.

Advertisement

Related Content

A Year To Remember For US Drug Launches
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Gilead's Epclusa Approved As First Pan-Genotypic HCV Therapy
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Venclexta Win Broadens AbbVie/Genentech CLL Positions
FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
Head Of The Class: A Star Stands Out Among 2014 Drug Launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098446

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel